Fulcrum Therapeutics
FULC
101 hedge funds and large institutions have $1.03B invested in Fulcrum Therapeutics in 2021 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 35 increasing their positions, 16 reducing their positions, and 8 closing their positions.
425% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 8
267% more capital invested
Capital invested by funds: $281M → $1.03B (+$751M)
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
119% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 16
51% more funds holding
Funds holding: 67 → 101 (+34)
10.98% more ownership
Funds ownership: 82% → 92.98% (+11%)
26% less call options, than puts
Call options by funds: $2.54M | Put options by funds: $3.44M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$69.5M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
+$23.7M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$22.4M |
| 4 |
D.E. Shaw & Co
New York
|
+$15.1M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$14.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGI
TRV GP III
Boston,
Massachusetts
|
-$18.9M |
| 2 |
CC
Casdin Capital
New York
|
-$12.1M |
| 3 |
Millennium Management
New York
|
-$9.97M |
| 4 |
AI
Alphabet Inc
Mountain View,
California
|
-$8.01M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$7.82M |
FULC Hedge Fund Activity: Q3 2021 in Review
101 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Fulcrum Therapeutics (FULC) for Q3 2021, worth a combined $1.03B — up 267% from $281M a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new FULC positions and 8 closed out — a net gain of 34 holders — while 35 added to existing stakes and 16 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $69.5M. The largest seller was TRV GP III, cutting an estimated $18.9M.
- 101 institutional investors held Fulcrum Therapeutics (FULC) as of Q3 2021, up from 67 in Q2 2021.
- Funds reported $1.03B of Fulcrum Therapeutics stock for Q3 2021, up 267% quarter-over-quarter.
- 42 funds opened new Fulcrum Therapeutics positions in Q3 2021 and 8 closed out, a net change of +34 holders.
- The largest Fulcrum Therapeutics buyer in Q3 2021 was Fidelity Investments, an estimated $69.5M added.
- The largest Fulcrum Therapeutics seller in Q3 2021 was TRV GP III, an estimated $18.9M sold.
Based on aggregated 13F filings for Q3 2021.